Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.
Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan.
J Control Release. 2022 Aug;348:648-659. doi: 10.1016/j.jconrel.2022.06.017. Epub 2022 Jun 18.
The use of lipid nanoparticles (LNPs) for nucleic acid delivery is now becoming a promising strategy with a number of clinical trials as vaccines or as novel therapies against a variety of genetic and infectious diseases. The use of microfluidics for the synthesis of the LNPs has attracted interest because of its considerable advantages over other conventional synthetic methods including scalability, reproducibility, and speed. However, despite the potential usefulness of large particles for nucleic acid delivery to dendritic cells (DCs) as a vaccine, the particle size of the LNPs prepared using microfluidics is typically limited to approximately from 30 to 100 nm. In this study, focusing on Derjaguin-Landau-Verwey-Overbeek (DLVO) theory, the effect of some synthetic parameters, including total flow rate, flow rate ratio, buffer pH, lipid concentration, molar ratio of PEG-lipid as well as salt concentration, on particle size was systematically examined by means of the design of experiment approaches. The findings indicated that the simple addition of salt (e.g. NaCl) to a buffer containing nucleic acids contributed greatly to the synthesis of large LNPs over 200 nm and this effect was concentration-dependent with respect to the salt. The effect of salt on particle size was consistent with a Hofmeister series. The systemic injection of larger mRNA-loaded LNPs resulted in a higher transgene expression in mouse splenic DCs, a higher activation of various splenic immune cells, and had a superior effect as a therapeutic cancer vaccine in a syngeneic mouse model compared to the smaller-sized counterpart with constant lipid composition prepared with lower NaCl concentration. Collectively, size-regulation by the simple addition of salt is a promising strategy for developing potent LNPs.
脂质纳米粒 (LNP) 用于核酸递送现在成为一种很有前途的策略,许多临床试验将其用作疫苗或针对各种遗传和传染性疾病的新型疗法。由于其在可扩展性、重现性和速度等方面优于其他传统合成方法,因此使用微流控技术合成 LNPs 引起了人们的兴趣。然而,尽管大颗粒在作为疫苗将核酸递送至树突状细胞 (DC) 方面具有潜在的用途,但使用微流控技术制备的 LNPs 的粒径通常限制在约 30 至 100nm 左右。在这项研究中,我们重点关注德加古因-兰德澳-沃韦尔贝克 (DLVO) 理论,通过实验设计方法系统地研究了一些合成参数(包括总流速、流速比、缓冲液 pH 值、脂质浓度、PEG-脂质的摩尔比以及盐浓度)对粒径的影响。研究结果表明,在含有核酸的缓冲液中简单添加盐(例如 NaCl)极大地有助于合成超过 200nm 的大 LNPs,并且这种效应与盐的浓度有关。盐对粒径的影响与豪夫迈斯特序列一致。较大的 mRNA 负载 LNPs 的全身注射导致小鼠脾脏 DC 中转基因表达更高,各种脾脏免疫细胞的激活更高,并且在同基因小鼠模型中作为治疗性癌症疫苗的效果优于用较低 NaCl 浓度制备的具有恒定脂质组成的较小尺寸的对应物。总的来说,通过简单添加盐进行粒径调节是开发有效 LNPs 的一种很有前途的策略。